🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our very own Tim Showalter recently participated in a podcast with Rafeh Naqash, MD regarding a JCO Precision Oncology publication on the #MMAI model and its potential utility in non-metastatic castration resistant #prostatecancer. Check out the full podcast here: heyor.ca/PRFIH1

The Phase 3 PROSTATE-IQ trial, recently featured in Urology Times, is evaluating how the ArteraAI Prostate Test can help tailor ADT decisions after prostatectomy—reducing toxicity, preserving QoL, and advancing personalized prostate cancer care: urologytimes.com/view/phase-3-t…

Excited to share that Dr. Tim Showalter will speak at #OncologyConundrums 3.0 on May 3! His talk, “Multimodal Magic: The AI That Sees, Reads and Predicts,” will highlight the power of ArteraAI in radiation oncology. 🕐 12:25 PM Vienna | 3:55 PM IST #ArteraAI #RadiationOncology

The Artera team is heading to #ASCO25! We’re excited to present 3 studies on how our MMAI platform can personalize care in #prostatecancer, including therapy insights from the STAMPEDE trial data and post-RP risk stratification with UC San Francisco. #ArteraOnTheGo

That’s a wrap on #AUA25! 🎉 Great connecting with so many #Urology leaders and sharing with everyone how #ArteraAI is advancing prostate cancer care and avoiding unnecessary gambles. Thanks to everyone who stopped by! #ProstateCancer #PrecisionMedicine

That’s a wrap on #ESTRO2025! It was great to see the preliminary results from the ASTuTE trial showcasing how the #ArteraAI Prostate Test is impacting shared decision making around ST-ADT usage. Proud to help shape the future of AI in oncology. #ProstateCancer #ArteraOnTheGo

Making prostate cancer treatment decisions can be overwhelming. The ArteraAI Prostate Test uses AI to analyze your biopsy + clinical info—helping you and your doctor choose the path that’s right for you. Learn more: artera.ai/for-patients

Amazing news—Artera CEO Andre Esteva, PhD has been named to the #TIME100Health 2025 list! 🎉 Proud to see his leadership in #AI and #precisionmedicine recognized on the global stage. Read more: time.com/collections/ti…

A new study in JCO Clinical Cancer Informatics validates Artera’s MMAI model, showing no evidence of algorithmic bias—a major step for racial equity in #prostatecancer care. This research reinforces the importance of diverse AI training for better patient outcomes: hitconsultant.net/2025/05/09/ai-…

Shoutout to our CMO, Dr. Tim Showalter for sharing his expertise in this Fox News piece on advances in #prostatecancer testing. We’re super lucky to have him helping us stay at the forefront of prostate cancer care. Read more: heyor.ca/izqBhC

At #ArteraAI, we subject our #MMAI platform to extensive validations. We recently published 2 different studies in Journal of Urology and Clinical Cancer Research, looking at the utility of our prognostic tests for patients that underwent #prostatectomy. heyor.ca/cbAz4P heyor.ca/m5aZVG

We’re proud to have Marc Benioff on Artera’s board, helping shape how AI transforms precision medicine. Check out his latest interview on the future of AI in business via Chief Executive: heyor.ca/mpLN8u #AIinHealthcare #MarcBenioff #Leadership

The Artera team is heading to #ASCO25! We’re excited to present 2 studies on how our MMAI platform can personalize care in #prostatecancer, including therapy insights from the STAMPEDE trial data and post-RP risk stratification with UC San Francisco. #ArteraOnTheGo

How can #AI help men with #prostatecancer choose between active surveillance & treatment? David B. Nash MD,MBA shares his own story and highlights the important role AI can play in precision care, and the power of the #ArteraAI Prostate Test, in @MedPageToday: medpagetoday.com/opinion/focuso…

Join us June 10 @ 6:30 PM ET for a live webinar on the Artera Prostate Test! Hear how clinicians are using it to guide care across the spectrum of risk groups and treatment scenarios. 🧠 Dr. Chao | Dr. Nepple | Dr. Zouain 🔗 Register: heyor.ca/sG0RkN

With #ASCO2025 underway, it's exciting to see all the new innovations coming out that will improve #prostatecancer care. We're proud to partner with key collaborators like Nick James also on @Prof-Nick-James.bsky.social, AttardLab and Matt Hobbs in leveraging #MMAI. heyor.ca/bQunwh.

Tune in for the next episode of Real World Wednesday on June 4 at 11 AM EDT, featuring Artera’s VP of Clinical Development, Dr. Erin Stewart! You won’t want to miss this deep dive into real-world data and the future of #AI in #oncology. Tune in here: heyor.ca/8K2YJY

Artera is heading to #ABSBrachy25 next week in Nashville! Looking forward to connecting and sharing how AI is shaping the future of prostate cancer care. #Brachytherapy #RadiationOncology #AIinHealthcare

Just announced at #ASCO25: The ArteraAI Prostate Test is now enhanced for high-risk localized prostate cancer—helping identify which patients benefit from abiraterone and who may safely avoid added toxicity, cost, and complexity: itnonline.com/content/prosta…

Want to hear from current #ArteraAI Prostate Test users Drs. Nicolas Zouain and Kenneth Nepple on how to utilize the test results to inform clinical decision making? Register now for our webinar on 6/10 to get all your questions answered.